What is the optimum dose of type A botulinum toxin for treating neurogenic bladder overactivity?

Ruffion, A.; Capelle, Olivier; Paparel, P.; Leriche, B; Leriche, A.; Grise, P.

doi:10.1111/j.1464-410x.2006.06091.x

Cited by 57 publications

(45 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…However, the study duration of 24 weeks limits the conclusions that may be made with respect to injection duration. In contrast, Ruffion et al concluded that 1000 SU Dysport® was associated with a significantly longer duration of action (10.4 vs. 4.8 months) when compared to 500 SU (20). In those patients initially receiving 500 SU who went on to receive repeat injections using 1000 SU, the duration increased consistent with those patients initially receiving 1000 SU.…”

Section: Injection Dose Duration Outcomesmentioning

confidence: 66%

“…However, no specific data regarding repeat injection is provided in this report. Ruffion et al report repeat Dysport® injection (500 versus 1000 SU) in 36 patients (20). In those patients receiving an initial dose of 1000 SU, there have been no treatment failures.…”

Section: Repeat Injectionmentioning

confidence: 99%

“…Recently, Ruffion et al investigated the benefit of 500 versus 1000 SU of Dysport® in the treatment of NDO (20). Following toxin injection, 76% of patients were found to be completely dry using both doses.…”

Section: Protocol For Botulinum Toxin Injection Injection Dose Efficmentioning

confidence: 99%

See 2 more Smart Citations

Botulinum toxin injection: a review of injection principles and protocols

2007

View full text Add to dashboard Cite

Despite the favorable outcomes seen using botulinum toxin (BTX) for voiding dysfunction using BTX, a standardized technique and protocol for toxin injection is not defined. We reviewed the current literature on intravesical BTX injection for DO (detrusor overactivity). Specific attention was placed on defining optimal injection protocol, including dose, volume, and injection sites. In addition, we sought to describe a standard technique to BTX injection.

show abstract

Section: Injection Dose Duration Outcomesmentioning

confidence: 66%

Section: Repeat Injectionmentioning

confidence: 99%

See 1 more Smart Citation

Botulinum toxin injection: a review of injection principles and protocols

2007

View full text Add to dashboard Cite

show abstract

“…Two of them, a woman with paraplegia and a woman with tetraplegia, suffered from transient generalized weakness after receiving 1500 units of abobotulinumtoxinA, which corresponds to approximately 500 units of onabotulinumtoxinA. 36,37 The three other cases included two men with tetraplegia and one woman with paraplegia who suffered from transient weakness that negatively interfered with their ability to carry out transfers after receiving 300 units of onabotu-…”

Section: Possible Complications Of Botulinum Toxinmentioning

confidence: 99%

Advances in the Management of Neurogenic Detrusor Overactivity in Multiple Sclerosis

Yonnet

Fjeldstad²,

Carlson

et al. 2013

International Journal of MS Care

View full text Add to dashboard Cite

Bladder dysfunction in multiple sclerosis (MS) can be socially disabling, have negative psychological and economic consequences, and impair patients' quality of life. Knowledge of the functional anatomy and physiology of the urinary tract is essential to understand the symptoms associated with central nervous system lesions and the pharmacotherapies used to treat them. Treatments for neurogenic detrusor overactivity (NDO) have consisted mainly of administration of anticholinergic drugs, which have been shown to provide suboptimal clinical benefits and be poorly tolerated. The US Food and Drug Administration (FDA) approval of intravesicular botulinum toxin therapy provides a secondline option for MS patients with NDO not responsive to anticholinergic drugs. We performed a review of key literature pertaining to the intravesicular application of botulinum toxin. In the management of NDO, administration of intravesicular botulinum toxin using clean intermittent catheterization decreases the incidence of urinary tract infections, promotes urinary continence, and improves quality of life for 9 months after a single injection; moreover, those benefits are maintained with repeated injections over time. Int J MS Care. 2013;15:66-72.

show abstract

“…The mechanism of action, at least on the motor side, is ultimately by interrupting the fusion of vesicles containing Ach to the plasma membrane of the peripheral cholinergic terminals. Thus, it prevents the release of Ach at the neuromuscular junction, resulting in flaccid paralysis of the muscle 18 . The aim of this study is to evaluate and compare the efficacy of BTX-A injections in the treatment of detrusor over activity in IDO and in NDO.…”

Section: Introductionmentioning

confidence: 99%

The effectiveness of intravesical Botox in idiopathic and non-idiopathic detrusor over activity

Ismail

Koye

2011

ZJMS

View full text Add to dashboard Cite

Background and objectives:We have evaluated and compared the efficacy of Botox® in the treatment of bladder over activity in Idiopathic detrusor over activity (IDO) and Neuropathic detrusor over activity (NDO) in a tertiary centre. We hypothesised that the outcome of this less invasive treatment would be more promising in patients with IDO than those with NDO.Methods: A total of 229 patients were reviewed with overactive bladder proven by urodynamic studies over the last 2 years. Of these, 174 patients received Botox® injection. 132 (75%) patients had IDO and 42 (25%) patients had NDO. 200 IU of Botox® was injected per patient in the IDO group and 300 IU in the neurogenic group. Results: Eighty one of 118 (68.7%) known patients with IDO reported being dry after receiving the Botox® compared to 20/39 (51.3%) patients with NDO. Whereas, 88/118 (68.7%) patients with IDO reported significant satisfaction compared to 25/39 (64.1%) patients with NDO. Conclusion: Botox® is an effective, minimally invasive treatment for drug refractory IDO + NDO. In comparison, patient reported satisfaction and dryness with the procedure was statistically the same. However, the IDO group responded slightly better to treatment. The average mean effect was the same in both groups. Key words: Botox, Idiopathic detrusor over activity (IDO), Neuropathic detrusor over activity (NDO). Abstract

show abstract

What is the optimum dose of type A botulinum toxin for treating neurogenic bladder overactivity?

Cited by 57 publications

References 28 publications

Botulinum toxin injection: a review of injection principles and protocols

Botulinum toxin injection: a review of injection principles and protocols

Advances in the Management of Neurogenic Detrusor Overactivity in Multiple Sclerosis

The effectiveness of intravesical Botox in idiopathic and non-idiopathic detrusor over activity

Contact Info

Product

Resources

About